Weekly Investment Analysts’ Ratings Changes for AngioDynamics (ANGO)

Share on StockTwits

A number of research firms have changed their ratings and price targets for AngioDynamics (NASDAQ: ANGO):

  • 10/8/2019 – AngioDynamics was downgraded by analysts at BidaskClub from a “sell” rating to a “strong sell” rating.
  • 10/5/2019 – AngioDynamics was downgraded by analysts at ValuEngine from a “buy” rating to a “hold” rating.
  • 10/4/2019 – AngioDynamics had its price target lowered by analysts at KeyCorp from $30.00 to $21.00. They now have an “overweight” rating on the stock.
  • 10/3/2019 – AngioDynamics was downgraded by analysts at TheStreet from a “c” rating to a “d+” rating.
  • 8/31/2019 – AngioDynamics was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.

ANGO traded down $0.26 on Tuesday, hitting $14.46. The company’s stock had a trading volume of 259,780 shares, compared to its average volume of 226,185. The company’s 50 day simple moving average is $16.98 and its 200-day simple moving average is $19.36. The firm has a market cap of $550.38 million, a P/E ratio of 17.42 and a beta of 0.71. AngioDynamics, Inc. has a 12 month low of $13.72 and a 12 month high of $25.48.

AngioDynamics (NASDAQ:ANGO) last released its quarterly earnings data on Thursday, October 3rd. The medical instruments supplier reported $0.08 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.04 by $0.04. The company had revenue of $66.00 million during the quarter, compared to the consensus estimate of $67.74 million. AngioDynamics had a net margin of 17.79% and a return on equity of 4.89%. AngioDynamics’s revenue for the quarter was up 3.3% on a year-over-year basis. During the same period last year, the firm earned $0.16 EPS. Research analysts anticipate that AngioDynamics, Inc. will post 0.12 EPS for the current year.

Large investors have recently made changes to their positions in the business. Keybank National Association OH boosted its holdings in AngioDynamics by 41.8% in the 2nd quarter. Keybank National Association OH now owns 66,670 shares of the medical instruments supplier’s stock valued at $1,313,000 after purchasing an additional 19,650 shares during the period. Nuveen Asset Management LLC bought a new position in AngioDynamics in the 2nd quarter valued at $4,865,000. Fort Washington Investment Advisors Inc. OH boosted its holdings in AngioDynamics by 0.8% in the 2nd quarter. Fort Washington Investment Advisors Inc. OH now owns 651,319 shares of the medical instruments supplier’s stock valued at $12,824,000 after purchasing an additional 5,000 shares during the period. Swiss National Bank boosted its holdings in AngioDynamics by 2.1% in the 2nd quarter. Swiss National Bank now owns 69,100 shares of the medical instruments supplier’s stock valued at $1,361,000 after purchasing an additional 1,400 shares during the period. Finally, Price T Rowe Associates Inc. MD boosted its holdings in AngioDynamics by 27.1% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 607,751 shares of the medical instruments supplier’s stock valued at $11,967,000 after purchasing an additional 129,497 shares during the period. 98.58% of the stock is owned by hedge funds and other institutional investors.

AngioDynamics, Inc designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company provides AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support.

See Also: What does EPS mean?

Receive News & Ratings for AngioDynamics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics Inc and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Bel Fuse, Inc.  Plans $0.07 Quarterly Dividend
Bel Fuse, Inc. Plans $0.07 Quarterly Dividend
Brokerages Set Kirkland’s, Inc.  Price Target at $3.20
Brokerages Set Kirkland’s, Inc. Price Target at $3.20
Piper Jaffray Companies Research Analysts Lower Earnings Estimates for Ultragenyx Pharmaceutical Inc
Piper Jaffray Companies Research Analysts Lower Earnings Estimates for Ultragenyx Pharmaceutical Inc
Tecnoglass Inc to Issue Quarterly Dividend of $0.14
Tecnoglass Inc to Issue Quarterly Dividend of $0.14
Zacks: Analysts Expect Pebblebrook Hotel Trust  Will Announce Earnings of $0.51 Per Share
Zacks: Analysts Expect Pebblebrook Hotel Trust Will Announce Earnings of $0.51 Per Share
Park Lawn Corp  Receives C$32.29 Average PT from Analysts
Park Lawn Corp Receives C$32.29 Average PT from Analysts


© 2006-2019 Ticker Report